Acute monocytic leukemia: Difference between revisions
m (Robot: Changing Category:Disease state to Category:Disease) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 14: | Line 14: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 33: | Line 33: | ||
{{Hematology}} | {{Hematology}} | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 20:41, 8 August 2012
| Acute monocytic leukemia | |
| ICD-10 | C93.0 |
|---|---|
| ICD-9 | 206.0 |
| MeSH | D007948 |
Template:Search infobox Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Acute monocytic leukemia (AMoL, or AML-M5) is considered a type of acute myeloid leukemia. In order to fulfill World Health Organization (WHO) criteria for AML-5, a patient must have greater than 20% blasts in the bone marrow, and of these, greater than 80% must be of the monocytic lineage. A further subclassification (M5a versus M5b) is made depending on whether the monocytic cells are predominantly monoblasts (>80%) (acute monoblastic leukemia) or a mixture of monoblasts and promonocytes (<80% blasts). Monoblasts can be distinguished by having a roughly circular nucleus, delicate lacy chromatin, and abundant, often basophilic cytoplasm. These cells may also have pseudopods. By contrast, promonocytes have a more convoluted nucleus, and their cytoplasm may contain metachromatic granules. Monoblasts are typically MPO negative and promonocytes are MPO variable. Both monoblasts and promonocytes stain positive for non-specific esterase (NSE), however NSE may often be negative.
Immunophenotypically, M5-AML variably express myeloid (CD13, CD33) and monocytic (CD11b, CD11c) markers. Cells may aberrantly express B cels marker CD20 and the NK marker CD56. Monoblasts may be positive for CD34.
M5 is associated with characteristic chromosomal abnormalities, often involving 11q23 or t(9;11)affecting the MLL locus, however the MLL translocation is also found in other AML subtypes. MLL is believed to be prognostically unfavorable in AML-M5 compared to other genetic alterations involving MLL such as t(9;11) The t(8;16) translocation in MLL is associated with hemophagocytosis.
AML-M5 is thought to be associated with exposure to epidophyllotoxins.
AML-M5 is treated with intensive chemotherapy (such as anthracyclines) or with bone marrow transplantation.